Are There Challenges in Targeting G Proteins for Cancer Treatment?
Despite their potential, targeting G proteins in cancer therapy presents several challenges. The ubiquitous nature of G proteins in various physiological processes means that targeting them can lead to significant side effects. Additionally, the complexity and redundancy of signaling pathways complicate the development of highly specific inhibitors. Resistance mechanisms, such as mutations in downstream signaling components, can also diminish the efficacy of G protein-targeted therapies.
